Nasdaq Iceland has approved Alvotech S.A’s (“Alvotech”) request for admission to trading of its shares on the Nasdaq Iceland Main Market (“Main Market”). Alvotech’s shares will be admitted to trading on the Main Market following the passporting of Alvotech’s prospectus to Iceland.
Hafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating Officer Mark Levick has decided to step down as Chief Executive Officer and Robert Wessman, Executive Chairman and founder, will become CEO Changes to the leadership team are effective January
Alvotech S.A. (“Alvotech”) has submitted its application to Nasdaq Iceland for admission of its shares for trading on the Nasdaq Iceland Main Market under the ticker symbol “ALVO”. The application awaits approval from Nasdaq Iceland. Alvotech’s shares are currently listed on the Nasdaq Stock Market
Existing senior bonds upsized by $70 million with additional investment from a consortium of institutional investors Alvotech acquires the Reykjavik manufacturing facility, previously utilized under a long-term lease agreement, and secures approximately $16 million, at current exchange rates, in
Revenue for first nine months of 2022 increased to $59.2 million, compared to $2.0 million for the same period in 2021 Discussions with U.S. FDA progressed regarding both biologic license applications for AVT02 (adalimumab); aiming to launch in the U.S., if approved, on July 1, 2023; additional
Increases availability of cost-effective high-concentration low-volume adalimumab in Australia First approved biosimilar from the partnership with Cipla, which also includes four other biosimilar candidates REYKJAVIK, Iceland and MUMBAI, India, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:
Alvotech will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02 The switching study was conducted to investigate the pharmacokinetics, immunogenicity, efficacy and safety in patients undergoing repeated switches between Humira and AVT02 Alvotech is
REYKJAVIK, Iceland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2022, after U.S.
REYKJAVIK, Iceland , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in the Jefferies London Healthcare
Expanded partnership covers biosimilar candidates in immunology and oncology REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients